Cytodyn Inc (CYDY)

[BlackDoggie]

Yes. By quite a bit. Assuming it actually turned $500mm in revenue, if it were to trade at a (ridiculous...) P/E of 1x, we'd be at $2/share currently ignoring costs of business, etc. That doesn't factor in the warrants that would be exercised, for those who will certainly bring it up.

For fun, consider the following P/E ratios. Admittedly from mature companies, etc.

GSK: 40x
GILD: 56x
JAZZ: 18x

JAZZ may be the most fun comparison. 2017? $488mm net income on $1,618mm total revenue. 60mm shares outstanding (edit: about 10% of CYDY's current share cap) for the neighborhood of $8.15 trailing EPS. $150/share today. I'm mixing a few time frames and conventions for the sake of simplicity, but the point holds pretty well. CYDY isn't trading in the real world at the moment.

https://finance.yahoo.com/quote/JAZZ?p=JAZZ

JAZZ traded at $0.89 in March of '09. It traded at $8 in September of '09.

With this in mind, I'll go back to my earlier question that I posted (what must this thing really be worth...?) Consider these projections from management's presentations and/or discussions:

Prognostic test: $500mm annual revenue

HIV market (combo): $1.2B

HIV market (mono): $4B

Cancer: ...?

Think back to the numbers on JAZZ, then sleep better tonight with your CYDY investment.